iPulse AI Research Publications
Ten pharma and biotech forecasts reveal why the next AI advantage will belong to companies that can turn cheap prediction into clinical evidence, manufacturing, and patient outcomes.
Publication library
8 publications in the permanent iPulse AI archive.
Ten pharma and biotech forecasts reveal why the next AI advantage will belong to companies that can turn cheap prediction into clinical evidence, manufacturing, and patient outcomes.
Making an investment decision is easy. Making one without emotion, selective evidence, or false certainty is not. Our latest market-wide analysis shows why disagreement may be one of the most useful signals.
All 12 research models were bullish on LINK. The real question is whether adoption creates lasting value before dilution, competition, or one major exploit changes the story.
What SpaceX, PetroChina, and NuScale reveal about using model disagreement as a research tool instead of treating consensus as truth.
The problem with collapsing return, confidence, risk, financial strength, and catalysts into one number.
A 12-voice analysis framework ranked 400+ long-horizon opportunities. The best pick showed why upside alone is a dangerous way to read any forecast.
What three years of building iPulse AI taught us about trust, judgment, and the future of professional analysis
Every day, investors, analysts, advisors, and research teams are surrounded by price movement, earnings releases, macro data, geopolitical risk, social narratives, analyst opinions, model outputs, and news cycles that...
iPulse AI Investment Intelligence
Substack is the newsletter and discussion layer. This publication library remains the durable owned research record.